What does Rezolute, Inc. do?
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in…
What is Rezolute, Inc.'s P/E and P/B ratio?
Rezolute, Inc. has a P/E ratio of -5.1 and a P/B ratio of 3.20.
What is Rezolute, Inc.'s debt-to-equity ratio?
Rezolute, Inc. has a debt-to-equity ratio of 0.01.
How much does Rezolute, Inc. owe compared with what it owns?
Rezolute, Inc. owes $0.07 for every $1 it owns (balance sheet Mar 2026), which is low.
What is Rezolute, Inc.'s Positivity rank?
Rezolute, Inc. is ranked #2,843 of 6,774 companies globally and #1,038 of 4,000 in United States on PositoAI, with a Positivity Score of 21,093.
Does Rezolute, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Rezolute, Inc..
Where can I read the latest news about Rezolute, Inc.?
Recent headlines about Rezolute, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Rezolute, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Rezolute, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.